Global Genitourinary Tract Agents Market, By Drug Class (Impotence Agents, Tocolytic Agents, Urinary Antispasmodics, Uterotonic Agents, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Genitourinary Tract Agents Market Analysis and Size
The global genitourinary tract agents market is expected to witness significant growth during the forecast period The increasing occurrence of genitourinary disorders such as renal failure, benign prostatic hyperplasia (BPH), end-stage renal disease (ESRD), erectile dysfunction, and an growing number of pipeline drugs is expected to expand the market growth globally. Currently, 47 and 16 medications for cervical cancer are in the clinical development phase and phase-II stages respectively, that demonstrates the huge growing research platform. Developing markets and huge investment in research and development are the factors responsible for the growth of this market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global genitourinary tract agents market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Genitourinary tract agents are the type of pharmacological agents widely used for the disorders of reproductive organs, excretory system, or urinary tract. This consists of different medicines that either suppress uterine contractions or modifiers of urine pH or may relieve from bladder spasm. Patients suffering from diseases and infections associated with genitourinary systems have been depending on steroids and immunosuppressants, chemically synthesized and may reciprocate with severe side effects such as insomnia, nausea, vomiting, acne, and diarrhea.
Genitourinary Tract Agents Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Drug Class (Impotence Agents, Tocolytic Agents, Urinary Antispasmodics, Uterotonic Agents, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Novartis AG (Switzerland), Endo International Inc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Cipla Inc (India), Dr Reddy's Laboratories Ltd (India), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc (U.S.), Lupin (India), Abbvie Inc. (U.S.), Daiichi Sankyo, Inc (Japan), GenBioPro (U.S.), Ferring B.V. (Switzerland)
Global Genitourinary Tract Agents Market Dynamics
- Increased Product Launches
The rising number of product launches are helping in the market expansion. For instance, the FDA approved cefiderocol for patients 18 years and above in November 2019. There are no alternate treatment options for complicated urinary tract infections, including pyelonephritis caused by several gram-negative microorganisms. This boosts the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to expand the global market as most products are available in capsule form and tablet form and it is a very feasible route of administration.
- Increasing Urinary Tract Infections
As per the National Institute of Medicine in July 2020, urinary tract infection affects around 150 million people all over the globe. Additionally, around 11% of women visit one physician once a year at least for treatment of urinary tract infection. Urinary tract infections (UTIs) are among the most common microbial diseases that are affecting people of all ages. Globally, UTIs affect about 150 million people each year.
- Increasing Demand for Retail Pharmacies
The rise in the number of genitourinary tract therapeutics being delivered through retail pharmacies and the increase in the number of retail pharmacies in highly developed countries create opportunities for the growth of the market. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
- Lack of skilled professionals
The lack of skilled healthcare personnel who are unable to treat the patients with suitable treatments could limit the growth of the global genitourinary tract agents market over a forecast period.
- High Cost
The huge expenditure associated with genitourinary tract agents medications surely hamper the market growth.
This global genitourinary tract agents market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global genitourinary tract agents market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Genitourinary Tract Agents Market
COVID-19 has left a major global public impact practically every business. Its long-term consequences are expected to influence industry growth during the forecast period. The weekly rate of urinary tract infections diagnosis dropped slightly in the year 2020, which may have slowed the industry's growth in the recent months. ?According to the study published in the ADIAN Journal in December 2020, a significant decrease in Urinary tract infection (UTI) diagnoses because of the COVID-19 pandemic raises concern.
In the post-pandemic era, market is expected to flourish due to the upliftment and drift from the COVID-19 drugs and vaccines and rising focus on the production of genitourinary tract agents. Thus, this will significantly impact the genitourinary tract agents market.
- In February 2020, Allecra, which is a French pharmaceutical company, launched Exblifep. It is a combination of enmetazobactam, a novel extended-spectrum beta-lactamase inhibitor, and cefepime, a fourth-generation cephalosporin which met primary endpoints in a clinical trial for cUTIs.
Global Genitourinary Tract Agents Market Scope
The global genitourinary tract agents market is segmented on the basis of drug class, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Impotence Agents
- Tocolytic Agents
- Urinary Antispasmodics
- Uterotonic Agents
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Genitourinary Tract Agents Market Regional Analysis/Insights
The global genitourinary tract agents market is analysed and market size insights and trends are provided by drug class, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global genitourinary tract agents market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for global genitourinary tract agents market throughout the forecasted period due to the increase government initiatives and developing healthcare facilities.
Asia-Pacific dominates the market due to the rise cases of genitourinary diseases and increase in awareness about the genitourinary tract agents as well as advanced healthcare facilities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Genitourinary Tract Agents Market Share Analysis
The global genitourinary tract agents market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global genitourinary tract agents market
Key players operating in the global genitourinary tract agents market include:
- Novartis AG (Switzerland)
- Endo International Inc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Glenmark Pharmaceuticals Ltd (India)
- Cipla Inc (India)
- Dr Reddy's Laboratories Ltd (India)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc (U.S.)
- Lupin (India)
- Abbvie Inc. (U.S.)
- Daiichi Sankyo, Inc (Japan)
- GenBioPro (U.S.)
- Ferring B.V. (Switzerland)